Sibylla Biotech is a technology company.
Sibylla Biotech has raised $23.0M across 1 funding round.
Sibylla Biotech has raised $23.0M in total across 1 funding round.
# High-Level Overview
Sibylla Biotech is an early-stage biotechnology company, not a technology company in the traditional sense. Founded in 2017 and headquartered in Milan, Italy[2], Sibylla is a preclinical-stage drug discovery firm focused on developing small molecule protein degraders targeting oncological diseases[3]. The company's mission is to identify therapeutics against "undruggable" targets—proteins that have historically resisted conventional drug development approaches[1].
Sibylla serves the pharmaceutical and biotech industry by solving a critical problem: many disease-relevant proteins cannot be targeted with traditional small molecule drugs because they lack suitable binding pockets in their native, fully-folded state. The company addresses this by targeting proteins during their folding process, when they exist in intermediate conformations that are more amenable to drug binding[1]. Its lead candidate targets Cyclin D1, a protein implicated in various cancers[1], with additional pipeline focus on oncology targets like KRAS[4].
Sibylla's competitive advantages center on its proprietary platform technology:
Sibylla operates at the intersection of two major biotech trends: the growing focus on protein degradation as a therapeutic modality and the application of computational biology and physics-based approaches to drug discovery. The company's timing is advantageous—protein degradation has emerged as a validated therapeutic strategy (evidenced by FDA-approved PROTAC drugs), yet most approaches target proteins in their native state. Sibylla's folding-interference approach opens an entirely new design space for undruggable targets, potentially expanding the addressable market for small molecule therapeutics.
The company influences the broader ecosystem by demonstrating that European biotech can pioneer cutting-edge therapeutic modalities and attract significant capital, while also validating the value of cross-disciplinary scientific teams in solving intractable drug discovery problems.
Sibylla is positioned at a critical inflection point. With Series A funding secured and a Non-Executive Chair appointed, the company is preparing to advance its lead Cyclin D1 degrader into preclinical development and toward clinical trials[2]. Success here would validate the PPI-FIT platform and likely unlock additional funding for pipeline expansion.
The key question ahead is whether folding-interference degraders can achieve the same clinical efficacy and safety profile as other protein degradation approaches. If they do, Sibylla could establish a new standard for targeting previously undruggable oncology proteins—a market opportunity that extends far beyond its current pipeline. The company's ability to attract world-class board talent suggests investor confidence in this thesis, but clinical validation remains the ultimate test.
Sibylla Biotech has raised $23.0M in total across 1 funding round.
Sibylla Biotech's investors include Marianne Bjørdal, 3B Future Health Ventures (Helsinn Investment Fund), Claris Ventures, Seroba Life Sciences.
Sibylla Biotech has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series A in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $23.0M Series A | Marianne Bjørdal, 3B Future Health Ventures (Helsinn Investment Fund), Claris Ventures, Seroba Life Sciences |